These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16968578)

  • 1. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
    Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
    Binkley N; Ringe JD; Reed JI; Ljunggren O; Holick MF; Minne HW; Liu M; Lamotta A; West JA; Santora AC
    Bone; 2009 Apr; 44(4):639-47. PubMed ID: 19185560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
    Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
    Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL; Liao EY; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; De Peng Y; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L; Santora AC
    Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
    Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
    BMC Musculoskelet Disord; 2018 Jul; 19(1):210. PubMed ID: 29970059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.
    Kim KJ; Min YK; Koh JM; Chung YS; Kim KM; Byun DW; Kim IJ; Kim M; Kim SS; Min KW; Han KO; Park HM; Shin CS; Choi SH; Park JS; Chung DJ; Mok JO; Baek HS; Moon SH; Kim YS; Lim SK;
    Yonsei Med J; 2014 May; 55(3):715-24. PubMed ID: 24719139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
    Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
    Karaplis AC; Chouha F; Djandji M; Sampalis JS; Hanley DA
    Ann Pharmacother; 2011 May; 45(5):561-8. PubMed ID: 21521859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label study of treatment with alendronate sodium plus vitamin D in men and women with osteoporosis in Thailand.
    Songpatanasilp T; Rojanasthien S; Sugkraroek P; Ongphiphadhanakul B; Robert L; Robert CS; Luevitoonvechkij S; Santora AC
    BMC Musculoskelet Disord; 2018 Nov; 19(1):392. PubMed ID: 30400864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
    Chung HY; Chin SO; Kang MI; Koh JM; Moon SH; Yoon BK; Yoon HK; Chung YS; Park HM
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):699-704. PubMed ID: 21521310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
    Shapses SA; Kendler DL; Robson R; Hansen KE; Sherrell RM; Field MP; Woolf E; Berd Y; Mantz AM; Santora AC
    J Bone Miner Res; 2011 Aug; 26(8):1836-44. PubMed ID: 21448918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
    Giampà E; Di Bonito M; Ferretti V; Nuvoli G; Paoletti F; Piazzini M; Ranieri M; Tuveri MA; Vinicola V
    Minerva Endocrinol; 2019 Dec; 44(4):344-350. PubMed ID: 31971357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
    Chung HY; Koo J; Kwon SK; Kang MI; Moon SH; Park JY; Shin CS; Yoon BK; Yoon HK; Chang JS; Chung YS; Park HM
    Clin Interv Aging; 2013; 8():597-603. PubMed ID: 23761968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
    Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.